Replimune wins FDA approval after melanoma drug was twice rejected
RegulatoryapprovedPositive
AI Analysis
Summary
Replimune received FDA accelerated approval for its melanoma drug after two previous rejections. The approval marks a significant regulatory victory for the Massachusetts biotech following prior clashes with FDA leadership.
Outcome Details
accelerated approval after two previous rejections
Importance:9/10
Sentiment:
0.90
FDA approvalaccelerated approvalmelanomaprevious rejectionsregulatory victory
Related Companies
Read the original article
Published by Endpoints News on August 6, 2026 8:03 PM